NATURAL SITE PREFERENCE IN CANCER BIOLOGY
癌症生物学中的自然位点偏好
基本信息
- 批准号:2087719
- 负责人:
- 金额:$ 32.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1980
- 资助国家:美国
- 起止时间:1980-06-01 至 1997-04-30
- 项目状态:已结题
- 来源:
- 关键词:athymic mouse breast neoplasms carcinoma cell line cell transformation chromosome aberrations clone cells cytogenetics disease /disorder model female gene mutation growth factor homeostasis hormone related neoplasm /cancer hyperplasia karyotype mammary epithelium neoplasm /cancer genetics neoplasm /cancer invasiveness neoplastic cell neoplastic process oncogenes preneoplastic state southern blotting xenotransplantation
项目摘要
In the human breast, a spectrum of microscopic changes has been termed
proliferative breast disease (PBD). Although hyperplastic lesions are
observed in human breast, their role in disease progression is not
understood. The progression of histopathological features of PBD has
been correlated with increased risk for the development of invasive
carcinoma. The most serve form of these lesions are precursors of cancer
or simply markers of breasts likely to give rise to independent
neoplastic lesions. The focal and microscopic lesions of PBD provide
scant tissues for genetic or other biological analyses. A human cell
line (MCF10A) originated from spontaneous immortalization of breast
epithelial cells obtained from a patient with fibrocystic disease.
MCF10A cells do not survive in vivo in Nude or Nude/Beige mice. However,
T25 c-Ha-ras oncogene-transfected MCF10A cells (MCF10AneoT) form small
nodules in Nude/Beige mice. However, T24 c-Ha-ras oncogene-transfected
MCF10A cells (MCF10AneoT) form small nodules in Nude/Beige mice which
persist for at least one year, eventually progress to atypical
hyperplasia, and sporadically progress to carcinomas. MCF10AneoT appear
to be stem cells capable of indefinite proliferation and with a wide
range of differentiation from normal to atypical. By reestablishing
cells in tissue culture from lesions representing different stages in
in which persist for at least one year, eventually progress to atypical
hyperplasia, and sporadically progress to carcinomas. MCF10AneoT appear
to be stem cells capable of indefinite proliferation and different stages
in progression of MCF10AneoT through atypical hyperplasia to carcinomas,
we have been able to provide still snapshots of a dynamic process. These
cell lines continue to progress when reimplanted in vivo in Nude/Beige
mice but are sufficiently stable in vitro to provide the tools essential
for he genetic analysis of progression. Thus, we are able to interrupt
progression by placing cells in vitro and reinitiated progresses in vivo
precipitate overt progression observed in xenografts. This unique model
has great potential for analyzing genetic and epigenetic (i.eg., host-
mediated) events central to progression from normal to atypical
hyperplasia to carcinoma in the human breast. Our hypothesis is that
sequential genetic alterations precipitate changes in human breast
epithelial responses to normal homeostatic regulatory signals. We
hypothesize that the progression of the MCF10AneoT series to malignant
carcinomas is accompanied by changes in homeostatic responses similar to
those which we have described in the mouse, i.e., that tumorigenic
variants of MCF10AneoT will be stimulated by normal epithelium and be
stromal-responsive but not stromal-dependent. Although Ha-ras is not
frequently mutated in human breast cancer, we hypothesize that, in this
model, the ras mutation mimics the effect of other, more common genetic
perturbations and that subsequent alterations driving progression will
be the same in this human breast model as in the natural disease.
Therefore, analysis of genetic changes and homestatic responses with a
series of increasingly aggressive lines will be vitally relevant for the
understanding of early breast cancer progression. A multidisciplinary
attack combining cell biology, molecular biology, and cytogenetics will
be mounted to delineate genetic changes and changes in response to
homeostatic growth regulatory factors which occur at each sequential step
of progression to atypical hyperplasia, to carcinoma in situ, and to
invasive carcinoma in the MCF10AenoT.TG xenograft model.
在人的乳房中,被称为微观变化的光谱
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FRED Raymond MILLER其他文献
FRED Raymond MILLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FRED Raymond MILLER', 18)}}的其他基金
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
- 批准号:
6470342 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
- 批准号:
6849197 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
- 批准号:
6698074 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
MCF10DCIS.com as a preclinical chemopreventive screen
MCF10DCIS.com 作为临床前化学预防筛查
- 批准号:
6439397 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
MCF10DCIS.com as a preclinical chemopreventive screen
MCF10DCIS.com 作为临床前化学预防筛查
- 批准号:
6620013 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
- 批准号:
6623819 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
- 批准号:
2101948 - 财政年份:1993
- 资助金额:
$ 32.62万 - 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
- 批准号:
2101950 - 财政年份:1993
- 资助金额:
$ 32.62万 - 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
- 批准号:
2101949 - 财政年份:1993
- 资助金额:
$ 32.62万 - 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
- 批准号:
3204700 - 财政年份:1993
- 资助金额:
$ 32.62万 - 项目类别:
相似海外基金
Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
- 批准号:
nhmrc : 950215 - 财政年份:1995
- 资助金额:
$ 32.62万 - 项目类别:
NHMRC Project Grants